Evidence map›Paper›PMID 31791674›Full record

ArticleClinical therapeutics2019

Analyzing Missing Data in Perinatal Pharmacoepidemiology Research: Methodological Considerations to Limit the Risk of Bias.

Angela Lupattelli, Mollie E Wood, Hedvig Nordeng

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical therapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Data Synthesis Reinvented: Preserving Missing Patterns for Enhanced Analysis.IEEE transactions on knowledge and data engineering · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Preserving Missing Data Distribution in Synthetic Data.Proceedings of the ... International World-Wide Web Conference. International WWW Conference
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Angela LupattelliPharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Research Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway. Electronic address: angela.lupattelli@farmasi.uio.no.
Mollie E WoodDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Hedvig NordengPharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Research Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway; Department of Child Health and Development, Norwegian Institute of Public Health, Oslo, Norway.

Funding

CVD Epidemiology Training Program in Behavior, the Environment and Global HealthT32HL098048 · NHLBI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Goodarz Danaei, ERIC B RIMM · 2009 to 2026
$6.9M
NHLBI NIH HHS T32 HL098048
6 · The paper itself

Abstract

Pharmacoepidemiological studies on the safety of medication during pregnancy are all susceptible to missing data (ie, data that should have been recorded but for some reason were not). Missing data are ubiquitous, irrespective of the data source used. Bias can arise when incomplete data on confounders, outcome measures, pregnancy duration, or even cohort selection criteria are used to estimate prenatal exposure effects that would be obtained from the fully observed data, if these were available for each mother-child dyad. This commentary describes general missing data mechanisms and methods, and illustrates how missing data were handled in recent medication in pregnancy research, according to the utilized data source. We further present one applied example on missing data analysis within MoBa (the Norwegian Mother, Father and Child Cohort Study), and finally illustrate how the causal diagram framework can be helpful in assessing risk of bias due to missing data in perinatal pharmacoepidemiology research. We recommend that applied researchers limit missing data during data collection, carefully diagnose missingness, apply strategies for missing data mitigation under different assumptions, and finally include evaluations of robustness results under these assumptions. Following this set of recommendations can aid future perinatal pharmacoepidemiology research in avoiding the problems that result from failure to consider this important source of bias.

Indexed as

BiasBiomedical ResearchData CollectionDrug TherapyFemaleHumansPharmacoepidemiologyPregnancyMedication safetyMissing dataPharmacoepidemiologyPregnancy

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.